Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dew, would appreciate your assessment of the implications to Momenta of Xarelto's approval for treatment of DVT. Thanks and regards.
DRFAI, you are missing the point of their discussions. This is not about investing (either long or short) in Momenta. They never discuss price entry and exit points. It is really about providing us with information about the company and its science. It is an intellectual exercise for the public good.
Thanks Jbog, considering hedging my long position with May puts.
General ASCO question - CLDX is presenting data on June 6, but the announcement indicates that ASCO data will be available on May 20th.
Does this mean that all presented data is available on this date or is it still embargoed until the date of actual presentation?
Can anyone confirm that the abstract of the data being presented below on June 5th will be published by ASCO on May 20th?
Abstract Title: Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).
Presentation Date/Time: Saturday, June 5, 2010; 8:00 AM – 12:00 PM with poster discussion from 12:00 – 12:15 PM
Kei, after today's debacle with ONTY I don't think lending real money is possible. How about some Monopoly money, you could buy a few hotels. Cheers.
Hi Kei, hope you're right about GNVC, could use some good news today. Are you still holding ONTY? Regards.
Thanks for article. Will discuss at office tomorrow. Problem with some construction firms is that they are reluctant to downsize because premium trade workers are sometimes hard to rehire. Sometimes they try to bid on a non-union basis to keep workers who agree to the lower salary and benefits.
O/T
Bladerunner/Grandpatb,
My experience as an accountant for a firm in NY specializing in small business shows that in some respects both of you are right.
Legal firms are closing down because the demand for their services at inflated rates has dropped considerably. Other small businesses which we service are facing a similar demand reduction. Building contractors in the trades, such as plumbing, electrical etc are having their financing lines closed down by the banks. The reason is that these companies are losing money due to demand contraction in NY and the banks do not want to financing their losses.
The banks are using a very large brush in pursuing risk aversion while they try to rebuild their balance sheets. There appears to be a tendency to avoid loss recognition and higher capital requirements by not selling distressed assets at this time. Some insights are available in this Harvard business school study:
http://www.zerohedge.com/article/harvard-study-confirms-level-3-assets-burden-bank-balance-sheets-lead-information-uncertaint
Dew, I wonder whether companies paying US tax on repatriated profits would qualify for a foreign tax credit to avoid double taxation. The senior tax partner at my office may provide some insights into this area. Regards and season's greetings.
Dew. actually the advice is spot on, without a reliable car how can she pack up and leave him.
Dew, pre-market seems to like the results. Good shorting opportunity if as you say shares are available.
Biomaven, I will look at linked material this evening and see how this process works. Thanks.
Wallstarb, would appreciate your explanation of the trading dynamic that produces movement to the strike price during option expiration.
How does this produce profit to the participants/ Thanks.
Wallstarb, I am at a loss to understand the 10% drop in MNTA price last week followed by a 10% gain two days into this week. Is this reflecting some change in fundamentals or is it some form of technical and manipulative transactions?
Biomaven, I understand that some substantial investors in PolyMedix after meeting with the company are very enthusiastic about PMX-30063 an antibiotic in addition to their Heparin reversal agent. Have you any thoughts about the company's platform technology?
Thanks Dew for your evaluation update. I really have little interest in Mead Johnson and would welcome the slimmer BMY resulting from the exchange. The 5% dividend is a nice benefit during this trans-formative period.
Thanks, got it, "various timepoints" items as you noted.
Dew, any thoughts on the timing of this shelf registration? Can any strategic inferences be drawn?
io-io. the last change is listed on 12/1/09 as a "Protocol change", do you know what this change was? Thanks.
Thanks Dew, I am similarly inclined. Have little interest in Mead Johnson. Schwab requests reply by 12/9 with offer expiration 12/14.
Appreciate if you would provide later update on your decision.
Any board opinions on benefit of tendering in the upcoming BMY exchange for Mead Johnson. I recall some discussion on this board about the status of BMY post-exchange as a potential acquisition target. Comments appreciated.
O/T - Dragon, now let's not go elitist on me please. If you can remember the history of the IV Dendreon board at one point there was a splinter group formed call "Dendreon Old Guard board" which was an attempt to keep the true believers of the faith with a private board. In my opinion and I may have a few years on Grandpa, an open board is always best because it permits all views to be aired and discussed. Regards
You didn't need a Yahoo membership, that was an e-mail address that I have with yahoo. Still having trouble with finding account at IV but will keep trying. Thanks.
Grandpatb, perhaps you could e-mail me: biomund@yahoo.com about IV board name and rules to join this board. I already have an IV regular account. Thanks, biomund
Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
Oncothyreon
Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
SEATTLE, Nov. 16, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.
The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries. As a selected company, Oncothyreon will present data on PX-866 at Windhover's Therapeutic Area Partnerships conference on November 17-19, 2009, in Boston, MA.
PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Oncothyreon is currently conducting a Phase 1 trial of PX-866 in patients with advanced metastatic cancer. Based upon the results seen in this trial to date, including the preliminary data presented at the American Society of Oncology Annual Meeting (ASCO) earlier this year, Oncothyreon has made the decision to move PX-866 into Phase 2 clinical development in the first half of 2010. The Phase 2 development program is currently expected to include two or more trials of PX-866 in combination with chemotherapy or other targeted agents and as a single agent.
"Preliminary results from our ongoing trial of PX-866 have demonstrated that the activity of the target, PI-3 kinase, can be down-regulated at doses well below the maximally tolerated dose identified in the intermittent dosing arm," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "As reported at ASCO, we have also had several patients with prolonged stable disease. Based on these data, we are excited by our plan to advance this compound into Phase 2 development next year."
"Oncothyreon's PX-866 was selected following a screening using a strict set of judging criteria for the Top 10 award and it represents what our committee considered one of the most attractive oncology opportunities the industry has to offer," said Roger Longman, Managing Director of Windhover Information. "PX-866 has met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability."
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
Forward-Looking Statements
In order to provide Oncothyreon's investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, clinical and pre-clinical development activities, including our decision to move PX-866 into Phase 2 clinical development in the first half of 2010 or the possibility that we may obtain a partner for PX-866.
Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing our product candidates, the adequacy of financing and cash reserves on hand, changes in general accounting policies, general economic factors, achievement of the results we anticipate from our clinical trials with our products and pre-clinical development of our product candidates and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
Additional Information
Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov and on SEDAR at www.sedar.com.
SOURCE: Oncothyreon Inc.
Investor and Media Relations Contact: Julie Rathbun, Rathbun Communications, (206)
769-9219, ir@oncothyreon.com
Credit to Moonshooter on IV board
Any thoughts on why this stock traded 1.6 million shares on 11/10 with a high of 5.70 without any news and now 2 days later is 4.36?
I cannot imagine that the reported earnings would cause selling unless other news had been anticipated. Also Rodman & Renshaw issued a buy with favorable comments on the financials.
This is a portion of message posted by Nono704 on the InvestorVillage ONTY board-clearly they are interpreting the data completely different than you do. Tell me what numbers you did not like and what your expectations were and why. Thanks for your insights.
R&R's Opinion
Oncothyreon Inc. (ONTY: PRICE: $5.00; MARKET CAP: $128.3; Market Outperform;) - 3Q09 earnings; the Biomira-to-Oncothyreon transformation is almost complete
ONTY continues to control spending, preserving valuable cash runway. Oncothyreon released 3Q09 results tonight, continuing to keep spending in check, with a loss from operations of $2.8M, down 29% yoy, compared to a loss of $3.6M in 3Q08. R&D spending came in at $1.3M, down 61% yoy, compared to the $2.1M spent in 3Q08, while G&A for the quarter was $1.4M, down 50% yoy, vs. $2.1M in 3Q08. Net loss for the quarter was $5.9M or $0.24/share, but includes a $3.2M non-cash charge for the change in the fair value of the warrants issued with the May 2009 secondary offering. Importantly, Oncothyreon ended 3Q09 with $35M in cash, up 82% from the $19.2M in cash the company ended 2008 with, which at the current burn rate of ~$1M/month, gives ONTY three years worth of runway. We expect that the company will continue to be very cautious with its spending, and we expect additional cash infusions, in the form of milestone payments from Merck KGaA (FWB: MRK Not Rated), including one expected by YE09, and potential revenues from new partnerships with the small molecule oncology pipeline.
Exactly what do you mean by "not good"? Numbers were basically consistent with expectations.
Wallstarb, previously you recommended selling the price gains on dramatic volume spikes. Wouldn't your trading philosophy then suggest buying the price drops on volume spikes or am I misinterpreting your message here?
--- aka CYA and get promoted.
Io_Io, are you concerned about the listing requirement for GNVC and their need to do more financing probably similar to their last lousy funding?
That would be a pleasant experience, thanks eagle.
Yummy, as long as its not alive. Those tentacles can really smart, trust me, my wife feeds me that twice a week.
By the way io_io, have you been following the action and news reports, both financial and scientific on THLD the last few days?
Any comments?
Wallstarb, the volume in THLD does not seem excessive today. In your volume sell trigger concept did you sell into today's action?
Bless you Tiny Tim, my losses feel much better.
However I did buy some additional shares today even though I have some reservations about the overall level of the stock price given its past appreciation and lack of current anticipated news.
I also agree. This is a board on InvestorsHub and not ScienceHub or CellularBiologyHub and while one can argue the appropriate foundation for making an investment there are many factors which comprise the fundamentals of price determination. Having great science with 2 billion shares outstanding may not make for a very good investment. The realities of science, finance and perceptions all enter into the intersection of supply and demand and as such are, in my mind, the "fundamentals" of investing. Wallstarb brings his perspective to the process.
PGS had referred to the data as "crappy" and Dew appeared to agree with the negative assessment.
Thanks for posting.
Just as a reminder that in the last financing of the company in August, Merriman acted as the sole placement agent.